General Catalyst's Summa Bet: Heads GC Wins, Tails Patients Lose
Short summary
General Catalyst acquired Ohio nonprofit Summa Health through a shell company (HATCo) structured to guarantee profits for the VC firm regardless of patient outcomes or hospital performance. The author argues the deal's asymmetric payoff math and General Catalyst's pivot away from failed digital health investments expose this as a private equity play dressed up as healthcare transformation.
- The deal structure is mathematically rigged: General Catalyst profits no matter what happens to Summa Health or its patients, a heads-I-win-tails-you-lose setup the author says regulators and analysts failed to stop.
- General Catalyst created HATCo (named after CEO Hemant Taneja's initials) to finance a hospital buyout it couldn't afford through normal VC channels, then claimed it's neither VC nor private equity despite following that exact playbook.
- The acquisition signals General Catalyst is fleeing a dismal decade of digital health failures and poor returns by pivoting to hospital ownership—a desperate move outside its core venture wheelhouse.
Full summary
General Catalyst, led by CEO Hemant Taneja, just closed a deal to acquire Summa Health, a nonprofit hospital system in Akron, Ohio, through a shell company called HATCo (conveniently named after Taneja's initials). The author has been hammering on this deal for nearly two years, watching it survive pushback from advocacy groups and skeptical analysts. What bothers him most is the structure itself—General Catalyst created this acquisition vehicle specifically because it couldn't afford the hospital buyout on its own. The whole thing reads like a private equity play dressed up in venture capital clothing, complete with press releases about "long-term commitment" and "community-based healthcare." Marc Harrison, HATCo's co-founder, claims this isn't a VC or PE move, but the author isn't buying it.
The core problem is the math. General Catalyst set up an asymmetric payoff structure where the firm wins regardless of what happens to Summa Health or its patients. The author describes it as a "heads-I-win, tails-you-lose" deal—the house always wins, and in this case, the house is Taneja and General Catalyst. It's a straightforward game rigged in the acquirer's favor through the leveraged-debt buyout structure, yet somehow this obvious manipulation made it through regulatory approval.
Behind the deal lurks a bigger story: General Catalyst has spent the last decade chasing digital health investments that largely flopped, delivering lousy returns. Rather than own that failure, the firm is now pivoting to buying actual hospitals—playing wannabe private equity—seemingly to distract from its track record. The author sees this less as healthcare transformation and more as a Silicon Valley outfit using a nonprofit health system to rehabilitate its image and shore up its portfolio.